Use and importance of nonhuman primates in metabolic disease research

Current state of the field

Peter J Havel, Paul Kievit, Anthony G. Comuzzie, Andrew A. Bremer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Obesity and its multiple metabolic sequelae, including type 2 diabetes, cardiovascular disease, and fatty liver disease, are becoming increasingly widespread in both the developed and developing world. There is an urgent need to identify new approaches for the prevention and treatment of these costly and prevalent metabolic conditions. Accomplishing this will require the use of appropriate animal models for preclinical and translational investigations in metabolic disease research. Although studies in rodent models are often useful for target/pathway identification and testing hypotheses, there are important differences in metabolic physiology between rodents and primates, and experimental findings in rodent models have often failed to be successfully translated into new, clinically useful therapeutic modalities in humans. Nonhuman primates represent a valuable and physiologically relevant model that serve as a critical translational bridge between basic studies performed in rodent models and clinical studies in humans. The purpose of this review is to evaluate the evidence, including a number of specific examples, in support of the use of nonhuman primate models in metabolic disease research, as well as some of the disadvantages and limitations involved in the use of nonhuman primates. The evidence taken as a whole indicates that nonhuman primates are and will remain an indispensable resource for evaluating the efficacy and safety of novel therapeutic strategies targeting clinically important metabolic diseases, including dyslipidemia and atherosclerosis, type 2 diabetes, hepatic steatosis, steatohepatitis, and hepatic fibrosis, and potentially the cognitive decline and dementia associated with metabolic dysfunction, prior to taking these therapies into clinical trials in humans.

Original languageEnglish (US)
Pages (from-to)251-268
Number of pages18
JournalILAR Journal
Volume58
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Metabolic Diseases
metabolic diseases
Primates
rodents
Rodentia
fatty liver
Research
noninsulin-dependent diabetes mellitus
therapeutics
clinical trials
Fatty Liver
animal models
Type 2 Diabetes Mellitus
Medical problems
liver cirrhosis
dementia
complications (disease)
liver diseases
hyperlipidemia
atherosclerosis

Keywords

  • Baboon
  • Diabetes
  • Dyslipidemia
  • Fatty liver disease
  • Metabolic syndrome
  • Nonhuman primates
  • Obesity
  • Rhesus macaque

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Use and importance of nonhuman primates in metabolic disease research : Current state of the field. / Havel, Peter J; Kievit, Paul; Comuzzie, Anthony G.; Bremer, Andrew A.

In: ILAR Journal, Vol. 58, No. 2, 01.01.2017, p. 251-268.

Research output: Contribution to journalArticle

Havel, Peter J ; Kievit, Paul ; Comuzzie, Anthony G. ; Bremer, Andrew A. / Use and importance of nonhuman primates in metabolic disease research : Current state of the field. In: ILAR Journal. 2017 ; Vol. 58, No. 2. pp. 251-268.
@article{0c0116fb142142a6bc89d20f42ea47b3,
title = "Use and importance of nonhuman primates in metabolic disease research: Current state of the field",
abstract = "Obesity and its multiple metabolic sequelae, including type 2 diabetes, cardiovascular disease, and fatty liver disease, are becoming increasingly widespread in both the developed and developing world. There is an urgent need to identify new approaches for the prevention and treatment of these costly and prevalent metabolic conditions. Accomplishing this will require the use of appropriate animal models for preclinical and translational investigations in metabolic disease research. Although studies in rodent models are often useful for target/pathway identification and testing hypotheses, there are important differences in metabolic physiology between rodents and primates, and experimental findings in rodent models have often failed to be successfully translated into new, clinically useful therapeutic modalities in humans. Nonhuman primates represent a valuable and physiologically relevant model that serve as a critical translational bridge between basic studies performed in rodent models and clinical studies in humans. The purpose of this review is to evaluate the evidence, including a number of specific examples, in support of the use of nonhuman primate models in metabolic disease research, as well as some of the disadvantages and limitations involved in the use of nonhuman primates. The evidence taken as a whole indicates that nonhuman primates are and will remain an indispensable resource for evaluating the efficacy and safety of novel therapeutic strategies targeting clinically important metabolic diseases, including dyslipidemia and atherosclerosis, type 2 diabetes, hepatic steatosis, steatohepatitis, and hepatic fibrosis, and potentially the cognitive decline and dementia associated with metabolic dysfunction, prior to taking these therapies into clinical trials in humans.",
keywords = "Baboon, Diabetes, Dyslipidemia, Fatty liver disease, Metabolic syndrome, Nonhuman primates, Obesity, Rhesus macaque",
author = "Havel, {Peter J} and Paul Kievit and Comuzzie, {Anthony G.} and Bremer, {Andrew A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/ilar/ilx031",
language = "English (US)",
volume = "58",
pages = "251--268",
journal = "ILAR Journal",
issn = "1084-2020",
publisher = "Institute for Laboratory Animal Research",
number = "2",

}

TY - JOUR

T1 - Use and importance of nonhuman primates in metabolic disease research

T2 - Current state of the field

AU - Havel, Peter J

AU - Kievit, Paul

AU - Comuzzie, Anthony G.

AU - Bremer, Andrew A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Obesity and its multiple metabolic sequelae, including type 2 diabetes, cardiovascular disease, and fatty liver disease, are becoming increasingly widespread in both the developed and developing world. There is an urgent need to identify new approaches for the prevention and treatment of these costly and prevalent metabolic conditions. Accomplishing this will require the use of appropriate animal models for preclinical and translational investigations in metabolic disease research. Although studies in rodent models are often useful for target/pathway identification and testing hypotheses, there are important differences in metabolic physiology between rodents and primates, and experimental findings in rodent models have often failed to be successfully translated into new, clinically useful therapeutic modalities in humans. Nonhuman primates represent a valuable and physiologically relevant model that serve as a critical translational bridge between basic studies performed in rodent models and clinical studies in humans. The purpose of this review is to evaluate the evidence, including a number of specific examples, in support of the use of nonhuman primate models in metabolic disease research, as well as some of the disadvantages and limitations involved in the use of nonhuman primates. The evidence taken as a whole indicates that nonhuman primates are and will remain an indispensable resource for evaluating the efficacy and safety of novel therapeutic strategies targeting clinically important metabolic diseases, including dyslipidemia and atherosclerosis, type 2 diabetes, hepatic steatosis, steatohepatitis, and hepatic fibrosis, and potentially the cognitive decline and dementia associated with metabolic dysfunction, prior to taking these therapies into clinical trials in humans.

AB - Obesity and its multiple metabolic sequelae, including type 2 diabetes, cardiovascular disease, and fatty liver disease, are becoming increasingly widespread in both the developed and developing world. There is an urgent need to identify new approaches for the prevention and treatment of these costly and prevalent metabolic conditions. Accomplishing this will require the use of appropriate animal models for preclinical and translational investigations in metabolic disease research. Although studies in rodent models are often useful for target/pathway identification and testing hypotheses, there are important differences in metabolic physiology between rodents and primates, and experimental findings in rodent models have often failed to be successfully translated into new, clinically useful therapeutic modalities in humans. Nonhuman primates represent a valuable and physiologically relevant model that serve as a critical translational bridge between basic studies performed in rodent models and clinical studies in humans. The purpose of this review is to evaluate the evidence, including a number of specific examples, in support of the use of nonhuman primate models in metabolic disease research, as well as some of the disadvantages and limitations involved in the use of nonhuman primates. The evidence taken as a whole indicates that nonhuman primates are and will remain an indispensable resource for evaluating the efficacy and safety of novel therapeutic strategies targeting clinically important metabolic diseases, including dyslipidemia and atherosclerosis, type 2 diabetes, hepatic steatosis, steatohepatitis, and hepatic fibrosis, and potentially the cognitive decline and dementia associated with metabolic dysfunction, prior to taking these therapies into clinical trials in humans.

KW - Baboon

KW - Diabetes

KW - Dyslipidemia

KW - Fatty liver disease

KW - Metabolic syndrome

KW - Nonhuman primates

KW - Obesity

KW - Rhesus macaque

UR - http://www.scopus.com/inward/record.url?scp=85040798312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040798312&partnerID=8YFLogxK

U2 - 10.1093/ilar/ilx031

DO - 10.1093/ilar/ilx031

M3 - Article

VL - 58

SP - 251

EP - 268

JO - ILAR Journal

JF - ILAR Journal

SN - 1084-2020

IS - 2

ER -